LLY

984.76

+0.73%↑

JNJ

241.59

-0.56%↓

ABBV

219.68

-2.45%↓

NVS

153.09

-0.73%↓

AZN

190.11

-0.92%↓

LLY

984.76

+0.73%↑

JNJ

241.59

-0.56%↓

ABBV

219.68

-2.45%↓

NVS

153.09

-0.73%↓

AZN

190.11

-0.92%↓

LLY

984.76

+0.73%↑

JNJ

241.59

-0.56%↓

ABBV

219.68

-2.45%↓

NVS

153.09

-0.73%↓

AZN

190.11

-0.92%↓

LLY

984.76

+0.73%↑

JNJ

241.59

-0.56%↓

ABBV

219.68

-2.45%↓

NVS

153.09

-0.73%↓

AZN

190.11

-0.92%↓

LLY

984.76

+0.73%↑

JNJ

241.59

-0.56%↓

ABBV

219.68

-2.45%↓

NVS

153.09

-0.73%↓

AZN

190.11

-0.92%↓

Home・Akcijų sąrašas・Day One Biopharmaceuticals Inc

Day One Biopharmaceuticals Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

21.31 0.14

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

21.25

Max

21.31

Pagrindiniai rodikliai
By Trading Economics
Pajamos	-1.6M -21M
Pardavimai	14M 54M
Pelno marža	-39.611
Darbuotojai	178
EBITDA	-3.8M -23M

Rekomendacijos
By TipRanks
Rekomendacijos	Neutralu
12 mėnesių prognozė	-1.84% downside

Dividendai
By Dow Jones
Kitas uždarbis	2026-05-05

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	1B 2.2B
Ankstesnė atidarymo kaina	21.17
Ankstesnė uždarymo kaina	21.31

Naujienos nuotaikos

By Acuity

50%

153 / 351 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Very Strong Bearish Evidence

6.26 / 7.47 Palaikymas ir pasipriešinimas

Day One Biopharmaceuticals Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-03-12 23:12; UTC

Karštos akcijos

Stocks to Watch: Adobe, Mission Produce, Buzzfeed, Ulta

2026-03-12 22:15; UTC

Uždarbis

Wheaton Precious Metals Logs Higher 4Q Net Income, Boosts Dividend 18%

2026-03-12 21:42; UTC

Svarbiausios naujienos

Stryker Says Cyberattack Disruption Is Continuing

2026-03-12 21:29; UTC

Svarbiausios naujienos

Correction to War in Iran May Upend Brazil Central Bank's Plans Article

2026-03-12 21:27; UTC

Uždarbis

Adobe CEO to Depart as AI Boosts Sales -- Update

2026-03-12 20:46; UTC

Uždarbis

Adobe Posts Higher Sales With CEO Set to Depart

2026-03-12 20:21; UTC

Svarbiausios naujienos

Soybean Futures Higher on Instability in Iran --Daily Grain Highlights

2026-03-12 23:57; UTC

Rinkos pokalbiai

Gold Edges Higher Amid Ongoing Middle East Conflict -- Market Talk

2026-03-12 23:38; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2026-03-12 23:38; UTC

Rinkos pokalbiai

Nikkei May Fall, Tracking Wall Street's Losses -- Market Talk

2026-03-12 22:13; UTC

Uždarbis

Orient Overseas: Tariff Measures, Trade Tensions Weighed on Results >0316.HK

2026-03-12 22:13; UTC

Uždarbis

Orient Overseas: Middle East Situation Have Added to Future Uncertainity >0316.HK

2026-03-12 22:13; UTC

Uždarbis

Orient Overseas: Charter Market Remains Exceptionally Tight With Vessels in Short Supply >0316.HK

2026-03-12 22:13; UTC

Uždarbis

Orient Overseas 2025 Rev $9.72B Vs. $10.70B >0316.HK

2026-03-12 22:13; UTC

Uždarbis

Orient Overseas 2025 Net $1.51B Vs. Net $2.58 >0316.HK

2026-03-12 22:13; UTC

Rinkos pokalbiai

Uždarbis

Global Equities Roundup: Market Talk

2026-03-12 22:13; UTC

Rinkos pokalbiai

Uždarbis

Adobe Says Customers Want to Try AI Products for Free First -- Market Talk

2026-03-12 21:16; UTC

Įsigijimai, susijungimai, perėmimai

Alexander & Baldwin: JV Formed by Affil of MW Group and Funds Affiliated With Blackstone and DivcoWest Completed Acquisition of All Outstanding A&B Common Shrs >ALEX

2026-03-12 21:04; UTC

Uždarbis

Adobe Earnings Beat Is Overshadowed by CEO Departure. The Stock Is Sliding. -- Barrons.com

2026-03-12 21:02; UTC

Uždarbis

Wheaton Precious Metals 4Q Adj EPS $1.22 >WPM

2026-03-12 21:02; UTC

Uždarbis

Wheaton Precious Metals 4Q Sales $865M >WPM

2026-03-12 21:02; UTC

Uždarbis

Wheaton Precious Metals 4Q Net $558.3M >WPM

2026-03-12 21:02; UTC

Uždarbis

Wheaton Precious Metals 4Q EPS $1.23 >WPM

2026-03-12 20:57; UTC

Rinkos pokalbiai

Svarbiausios naujienos

No Need For Canada Rate Increases Amid Jump in Bond Yields -- Market Talk

2026-03-12 20:50; UTC

Rinkos pokalbiai

Financial Services Roundup: Market Talk

2026-03-12 20:50; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2026-03-12 20:15; UTC

Įsigijimai, susijungimai, perėmimai

Eaton Completes Acquisition Of Leading Liquid-cooling Solutions Provider Boyd Thermal, Creating An Industry-leading Grid-to-chip Solution For Data Centers >ETN

2026-03-12 20:10; UTC

Uždarbis

Adobe Sees 2Q Rev $6.43B-$6.48B >ADBE

2026-03-12 20:05; UTC

Uždarbis

Adobe 1Q Rev $6.4B >ADBE

2026-03-12 20:05; UTC

Uždarbis

Adobe Sees 2Q Adj EPS $5.80-Adj EPS $5.85 >ADBE

Akcijų palyginimas

Kainos pokytis

Day One Biopharmaceuticals Inc Prognozė

Kainos tikslas

By TipRanks

-1.84% į apačią

12 mėnesių prognozė

Vidutinis 20.86 USD -1.84%

Aukščiausias 21.5 USD

Žemiausias 17 USD

Remiantis 9 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Day One Biopharmaceuticals Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Neutralu

9 ratings

Pirkti

Laikyti

Parduoti

Remiantis 9 analitikų, pateikusių Day One Biopharmaceuticals Inc akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

6.26 / 7.47Palaikymas ir pasipriešinimas

Recent bearish events outweigh bullish events.

All events are bullish.

All events are bearish.

Rinkos nuotaikos

By Acuity

153 / 351 reitingas Sveikatos priežiūra

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Day One Biopharmaceuticals Inc

Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California.